Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATRON: PI-88 in Adjuvant HCC
NCT01402908Phase 3Terminated
- Sponsor
- Cellxpert Biotechnology Corp.
- Start
- Aug 2011
- Primary completion
- Jul 2014
- Modality
- Bivalent/Multivalent Binders
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing PI-88 with Placebo (2 arms). Primary endpoint: Disease-Free Survival. Started Aug 2011; status: terminated.
02
Drugs
Muparfostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01402908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01402908.